Biopharma AI
By
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
How Novartis and Relation Therapeutics’ $1.7 Billion AI Collaboration Redefine Drug Discovery Success Rates in Immunology, Atopic Diseases?
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing late-stage clinical failures•…
